Mark H Schoenfisch

Chapel Hill, NC, United States of America

Mark H Schoenfisch

This inventor holds 33 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Nitric Oxide Therapeutics. Top assignees: The University of North Carolina at Chapel Hill, Novan, Inc., Kwangwoon University Industry-Academic Collaboration Foundation. Active years: 2012-2025.

USPTO Granted Patents = 33 

% Patents Active = 90.9

 

 

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 222(Granted Patents)


Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Nitric Oxide
Biodegradable Polymers
Antibacterial Scaffolds
Hyperbranched Compounds
Mesoporous Silica
Microsensors
Polyglucosamines
Nanorods
Cyclodextrins
Macromolecules
S-Nitrosothiols
Wound Care
33 patents (USPTO):Explore Patents

Title: The Innovative Journey of Mark H. Schoenfisch

Introduction: Mark H. Schoenfisch, a pioneering inventor based in Chapel Hill, NC, has made significant contributions to the field of innovations and inventions with his groundbreaking work.

Latest Patents: Mark H. Schoenfisch holds several patents in the areas of biomedical engineering and nanotechnology, focusing on developing novel materials for medical applications.

Career Highlights: With a distinguished career spanning over two decades, Mark H. Schoenfisch has been at the forefront of cutting-edge research, particularly in the development of advanced healthcare technologies.

Collaborations: Throughout his career, Mark H. Schoenfisch has collaborated with leading researchers, scientists, and medical professionals to bring his innovative ideas to life and make a lasting impact in the industry.

Conclusion: Mark H. Schoenfisch's relentless pursuit of innovation and his passion for creating solutions that improve lives have solidified his reputation as a visionary inventor in the field of biomedical engineering.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…